<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Florence Roufosse, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy D Klion, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The hypereosinophilic syndromes (HES) are a group of disorders marked by the sustained overproduction of eosinophils, in which eosinophilic infiltration and mediator release cause damage to multiple organs. Although these disorders had long been considered idiopathic (eg, as in the "idiopathic hypereosinophilic syndrome," IHES), etiologies for some forms of HES have been described.</p><p>The clinical features, pathophysiology, and diagnosis of HES will be reviewed here. The treatment of these disorders is discussed separately, as is the initial approach to the patient with unexplained eosinophilia. (See  <a class="medical medical_review" href="/d/html/2210.html" rel="external">"Hypereosinophilic syndromes: Treatment"</a> and  <a class="medical medical_review" href="/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>A panel of experts reached consensus on terminology pertaining to hypereosinophilic conditions and published recommendations in 2012 [<a href="#rid1">1</a>]:</p><p class="headingAnchor" id="H11894263"><span class="h2">Hypereosinophilia</span><span class="headingEndMark"> — </span>Hypereosinophilia (HE) is defined as an absolute eosinophil count (AEC) &gt;1.5 x 10<sup>9</sup>/L (or &gt;1500 cells/microL) in the peripheral blood on two examinations separated in time by at least one month <strong>and/or</strong> pathologic confirmation of tissue HE.</p><p>For these purposes,<strong> tissue</strong> HE is defined by:</p><p class="bulletIndent1"><span class="glyph">●</span>On bone marrow section, a percentage of eosinophils that exceeds 20 percent of all nucleated cells, <strong>and/or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tissue infiltration that is extensive in the opinion of a pathologist (hematoxylin-eosin, May-Grunwald-Giemsa and Wright-Giemsa are the recommended stains for visualizing eosinophils in tissue section) <strong>and/or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Marked deposition of eosinophil granule proteins in tissue (in the absence or presence of major tissue infiltration by eosinophils). This is demonstrated by immunofluorescence and usually performed in expert centers. There is also a novel monoclonal antibody that recognizes eosinophil peroxidase, which can detect both tissue eosinophils and eosinophil degranulation [<a href="#rid2">2,3</a>].</p><p></p><p class="headingAnchor" id="H19581596"><span class="h2">Hypereosinophilic syndrome</span><span class="headingEndMark"> — </span>A hypereosinophilic syndrome (HES) is defined by the association of HE (as defined above), with eosinophil-mediated organ damage and/or dysfunction, provided other potential causes for the damage have been excluded.</p><p class="bulletIndent1"><span class="glyph">●</span>The term "HES" can therefore be used to qualify any condition characterized by eosinophilic infiltrates and associated complications, <strong>including situations where the cause of HE is identified</strong> (eg, restrictive cardiac disease occurring in the setting of parasitic infections [Löffler's endocarditis]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, the term "HES" should <strong>not</strong> be used when the clinical manifestations and underlying organ damage found in a hypereosinophilic patient can be explained by a mechanism <strong>other than</strong> HE. As an example, a patient with cardiovascular risk factors presenting with persistent HE and thoracic pain that is shown to be secondary to coronary artery occlusion, should not be diagnosed as HES, unless another clinical manifestation can be attributed to eosinophilic tissue infiltration.</p><p></p><p class="headingAnchor" id="H11894652"><span class="h3">Categories of HES</span><span class="headingEndMark"> — </span>HES are further subclassified according to the pathogenic mechanisms resulting in eosinophil expansion: primary, secondary, or idiopathic. (See <a class="local">'Pathophysiology'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary (or neoplastic) HES</strong> – In primary HES, eosinophilic expansion occurs in the setting of an underlying stem cell, myeloid, or eosinophilic neoplasm, and is considered (or proven) clonal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary (or reactive) HES</strong> – In secondary HES, eosinophilic expansion is driven by overproduction of eosinophilopoietic cytokines by other cell types and is polyclonal. This is typically the situation encountered in parasitic infections, certain solid tumors, and T cell lymphoma, wherein marked secondary HE may be responsible for organ damage and dysfunction. Lymphocytic variant HES (L-HES) is a subvariant in this category. (See <a class="local">'Diagnosis of L-HES'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic HES</strong> – In idiopathic hypereosinophilic syndrome (IHES), the underlying cause of HE remains unknown despite thorough etiologic work-up. The associated organ damage generally warrants therapeutic intervention.</p><p></p><p>In addition to HES, several other clinical situations associated with HE can be defined as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific syndromes associated with HE</strong>, in which the relative contribution of eosinophils to the clinical presentation and disease complications has not been fully elucidated, such as eosinophilic granulomatosis and polyangiitis (EGPA) and certain immunodeficiencies. (See  <a class="medical medical_review" href="/d/html/4347.html" rel="external">"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a> and  <a class="medical medical_review" href="/d/html/3960.html" rel="external">"Autosomal dominant hyperimmunoglobulin E syndrome"</a> and  <a class="medical medical_review" href="/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>"Hypereosinophilia of undetermined significance" (HE</strong><strong><sub>US</sub></strong><strong>),</strong> which describes patients with persistent unexplained HE, but without apparent complications related to tissue eosinophilia. This terminology highlights both the lack of an explanation for HE and the inability to predict whether the patient will eventually develop clinical manifestations related to eosinophilic organ infiltration, and thus progress to HES.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Hypereosinophilic syndrome (HES) is rare, and the true prevalence is unknown. In one study that used clinician coding of eosinophilia to identify patients with HES in the Surveillance, Epidemiology, and End Results (SEER) database, the estimated prevalence was between 0.36 to 6.3 per 100,000 [<a href="#rid4">4</a>].</p><p>Most patients are between 20 and 50 years of age at the time of diagnosis, although HES can develop in children [<a href="#rid5">5-7</a>]. One study suggested that the frequencies of clinical HES variants (including myeloproliferative variants) were similar in children and adults, although immunodeficiency presenting with HE was more common in children; children were also more likely to present with gastrointestinal complaints and had higher peak eosinophil counts than adults [<a href="#rid8">8</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Certain variants of HES (ie, those associated with aberrations in the gene for tyrosine kinase receptor platelet-derived growth factor receptor alpha [<em>PDGFRA</em>] and platelet-derived growth factor beta [<em>PDGFRB</em>]) occur almost exclusively in males, whereas others (lymphocytic variant HES [L-HES] and HES of unknown etiology) appear to be equally distributed between the sexes [<a href="#rid9">9,10</a>]. (See <a class="local">'HES variants'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>In hypereosinophilic syndrome (HES), eosinophils damage the tissues that they infiltrate. Common target organs include the skin, lung, and gastrointestinal tract. Less commonly, patients can have potentially life-threatening damage to the cardiovascular system and brain. Activated eosinophils may damage tissues in a number of mechanisms, which are described in more detail separately. (See  <a class="medical medical_review" href="/d/html/100544.html" rel="external">"Eosinophil biology and causes of eosinophilia"</a>.)</p><p>Eosinophils are derived from myeloid progenitors in the bone marrow, through the action of three hematopoietic cytokines: granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and interleukin-5 (IL-5). Of these three, only IL-5 is specific for eosinophil differentiation.</p><p class="headingAnchor" id="H5"><span class="h2">Mechanisms of eosinophil overproduction</span><span class="headingEndMark"> — </span>There is evidence that at least two distinct mechanisms can lead to dysregulated overproduction of eosinophils in patients with HES [<a href="#rid11">11,12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Clonal eosinophilic proliferation as a result of a primary molecular defect involving hematopoietic stem cells and/or defects in signal transduction from the receptors that mediate eosinophilopoiesis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overproduction of eosinophilopoietic cytokines, such as IL-5</p><p></p><p>In theory, HES could also result from defects in the normal suppressive regulation of eosinophil survival and activation, abnormalities in chemotaxis, or from functional abnormalities of the eosinophilopoietic cytokines, related to enhanced or prolonged biologic activity. However, these mechanisms have not been conclusively demonstrated.</p><p>Since the initial description of HES, progress has been made in identifying specific etiologic abnormalities that underlie hypereosinophilia (HE) in some patients with an HES occurring in the absence of an obvious cause (such as parasitic infection or drug allergy). These involve both of the above mentioned mechanisms: clonal eosinophil production (eg most significantly Fip1-like1-platelet-derived growth factor receptor alpha [<em>FIP1LI-PDGFRA</em>]) and reactive IL-5-driven eosinophil expansion (eg lymphocytic variant HES [L-HES]). In practice, once classical causes of HE have been ruled out (parasitic infection, etc), the underlying mechanism resulting in HE remains unknown despite thorough investigations in 70 to 80 percent of patients [<a href="#rid9">9,13-16</a>]. However, the true proportion of all patients with unexplained HE and identified abnormalities remains unknown, since the techniques used for identification have not been uniformly applied across series. Moreover, it is probable that each of the major investigative groups is affected by referral biases favoring HES patients with certain clinical presentations. Thus, while a specific center may observe a particular etiology to be common in its own patients with HES, this does not provide much information about prevalence in the broader population.</p><p class="headingAnchor" id="H6"><span class="h2">HES variants</span><span class="headingEndMark"> — </span>HES has been subdivided into several clinically relevant variants (<a class="graphic graphic_table graphicRef59869" href="/d/graphic/59869.html" rel="external">table 1</a>) [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Myeloproliferative variants of HES (M-HES).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>T lymphocytic variants of HES (L-HES).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial HES.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic HES (IHES).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Organ-restricted hypereosinophilic conditions – This term is applied to disorders with blood eosinophilia ≥1500/microliter in the setting of single organ involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specific/defined syndromes associated with HE — This term is applied to disorders with blood eosinophilia ≥1500/microliter in association with a distinct diagnosis, wherein the role of eosinophils in disease complications and clinical manifestations remains inconclusive.</p><p></p><p class="headingAnchor" id="H7"><span class="h3">Myeloproliferative HES variants</span><span class="headingEndMark"> — </span>A subgroup of patients with HES display features more typical of myeloproliferative disorders, including increased serum vitamin B12 levels, chromosomal abnormalities, anemia and/or thrombocytopenia, hepatomegaly, splenomegaly, and circulating leukocyte precursors [<a href="#rid5">5,18,19</a>]. These patients tend to be more refractory to glucocorticoid therapy. (See  <a class="medical medical_review" href="/d/html/2210.html" rel="external">"Hypereosinophilic syndromes: Treatment", section on 'Myeloid variants'</a>.)</p><p class="headingAnchor" id="H12440488"><span class="h4">Myeloproliferative neoplasms</span><span class="headingEndMark"> — </span>Some HES patients with myeloproliferative features have responded to treatment with tyrosine kinase inhibitors. Clonal chromosomal aberrations not recognizable by conventional cytogenetics have been demonstrated in the majority of these patients, leading to reclassification of this subset as having myeloproliferative neoplasms (MPN) [<a href="#rid19">19,20</a>]. Such patients fall into the category "primary/neoplastic hypereosinophilic syndromes" in the 2012 consensus classification proposal for eosinophilic conditions [<a href="#rid1">1</a>].</p><p>The World Health Organization (WHO) classification system of hematopoietic and lymphoid tissues includes a special category for myeloid and lymphoid disorders with eosinophilia and one of the following abnormalities [<a href="#rid21">21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>PDGFRA</em> – The gene encoding the tyrosine kinase receptor, platelet-derived growth factor receptor alpha, is located on chromosome 4 and may be involved in translocations with various fusion partners, most commonly due to an interstitial deletion on chromosome 4q12 resulting in a <em>FIP1L1</em>-<em>PDGFRA</em> fusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>PDGFRB</em> – The gene for the tyrosine kinase receptor, platelet-derived growth factor receptor beta [<a href="#rid10">10,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>FGFR1</em> – The gene for fibroblast growth factor receptor 1 is located on chromosome 8p11 and is often involved in a translocation with the <em>ZMYM2</em> gene (zinc finger, MYM2) on chromosome 13q12 [<a href="#rid23">23,24</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>PCM1-JAK2</em> – Myeloid neoplasm with t(8;9)(p22;q24.1), which results in the fusion of <em>PCM1</em> (pericentriolar material 1) and <em>JAK2</em> (Janus kinase 2) [<a href="#rid25">25-30</a>]. <em>PCM1-JAK2</em> is included as a provisional entity in the WHO classification system [<a href="#rid21">21</a>].</p><p></p><p>The most common chromosomal aberration is an interstitial deletion of chromosome 4q12, which creates the <em>FIP1L1</em>-<em>PDGFRA</em> fusion from Fip1-like1 (<em>FIP1L1</em>) and platelet-derived growth factor receptor alpha (<em>PDGFRA)</em>. The resultant protein, FIP1L1-PDGFRA, displays constitutive tyrosine kinase activity [<a href="#rid19">19,31-35</a>]. The prevalence of the <em>FIP1L1</em>-<em>PDGFRA</em> among patients fulfilling HES criteria is estimated to be between 10 and 14 percent, although this is not certain [<a href="#rid9">9,13,36</a>]. (See  <a class="medical medical_review" href="/d/html/2210.html" rel="external">"Hypereosinophilic syndromes: Treatment", section on 'Other tyrosine kinase inhibitors'</a>.)</p><p>M-HES may also be caused by other chromosomal rearrangements, including fusion of <em>PDGFRA</em> with other partner genes, rearrangements involving <em>PDGFRB</em>, or point mutations in <em>PDGFRA</em> [<a href="#rid10">10,22,37-40</a>]. There have also been case reports of HES with <em>JAK2</em> V617F and t(8;9)(p22;p24) creating <em>PCM1-JAK2</em> [<a href="#rid25">25-30,41,42</a>]. Clonal eosinophilia has also been noted in patients with <em>KIT</em>-positive systemic mastocytosis (<em>KIT</em> D816V) [<a href="#rid43">43</a>]. Neither <em>JAK2</em> V617F nor <em>KIT</em> D816V is typically imatinib-sensitive, but patients with <em>KIT</em> D816V may respond to <a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">midostaurin</a>. (See  <a class="medical medical_review" href="/d/html/4787.html" rel="external">"Advanced systemic mastocytosis: Management and prognosis", section on 'Midostaurin'</a>.)</p><p>Rare patients with IHES in whom bone marrow blasts are increased or clonality is documented (eg, by an abnormal karyotype or targeted next generation sequencing) have aggressive disease that is similar to that of chronic eosinophilic leukemia, not otherwise specified (CEL-NOS), [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H8"><span class="h3">T cell lymphocytic variants</span><span class="headingEndMark"> — </span>Lymphocytic variant HES (L-HES) is characterized by a predominance of skin and soft tissue involvement, although other clinical manifestations of HES, including cardiovascular, pulmonary, and rheumatological/articular involvement, are also present. In this variant, which is classified as a subvariant of secondary/reactive HES, IL-5-producing T cell subsets have been identified in the peripheral blood [<a href="#rid45">45</a>]. The most frequently reported abnormal T cell phenotype in L-HES is CD3-CD4+ [<a href="#rid46">46</a>]. In the largest cohort of patients with CD3-CD4+ associated L-HES reported, the majority of patients had elevated serum immunoglobulin E (IgE), skin involvement, and lymphadenopathy. Total lymphocyte counts were elevated in just one-third of patients [<a href="#rid46">46</a>]. The prevalence of this variant among all patients with HES is not well-defined. In one series of 60 patients with idiopathic eosinophilia, 16 were found to have abnormal IL-5-producing T cells [<a href="#rid14">14</a>]. This disorder may evolve to lymphoma [<a href="#rid45">45</a>]. (See <a class="local">'Skin disease'</a> below and <a class="local">'Laboratory features'</a> below.)</p><p>Molecular disease mechanisms remain largely unknown. However, one study identified a gain-of-function mutation in <em>STAT3</em> in isolated CD3-CD4+ T cells from one patient; two other patients had evidence for upregulation of STAT3-dependent pathways, but this mutation was not found [<a href="#rid47">47</a>]. A gain-of-function somatic mutation in <em>STAT5B</em> has also been described in two children presenting with L-HES [<a href="#rid48">48</a>]. </p><p>In addition to IL-5, the abnormal T cells produce other T helper type 2 (Th2) cytokines such as IL-4 and IL-13, as well as GM-CSF. The effects of these Th2 cytokines on other cells (eg, B cells) account for associated biologic features of L-HES. Indeed, B cell stimulation leads to increased IgE synthesis and polyclonal hypergammaglobulinemia [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Familial HES</span><span class="headingEndMark"> — </span>Autosomal dominant transmission of marked eosinophilia has been reported. In one family, eosinophilia began at birth and most family members remained asymptomatic, but progression with fatal endomyocardial fibrosis occurred in a few individuals; the gene was mapped to chromosome 5q31-33 [<a href="#rid50">50</a>]. In another family, IL-5 production by PBMC was increased, in the absence of IL-4 or IL-13 [<a href="#rid51">51</a>]. Familial forms also exist in several of the single-organ HES variants, including eosinophilic esophagitis and eosinophilic fasciitis and do not appear to differ in clinical presentation from the sporadic forms [<a href="#rid52">52-54</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Idiopathic HES</span><span class="headingEndMark"> — </span>Despite careful evaluation of HE, the etiology in as many as 75 percent of cases of presumed HES remains undefined. The terms "idiopathic HES" [<a href="#rid55">55</a>] and "HES of unknown etiology" are used to distinguish these patients from those in earlier series, which included patients with now defined subtypes. Among patients with multisystem organ involvement, some demonstrate features of myeloproliferative disease similar to those encountered in <em>FIP1L1-PDGFRA</em>-positive individuals, whereas others appear to have more of an "immuno-allergic" disorder suggesting possible involvement of T cells.</p><p class="headingAnchor" id="H11"><span class="h3">Organ-restricted hypereosinophilic conditions</span><span class="headingEndMark"> — </span>Organ-restricted hypereosinophilic conditions are defined as single organ involvement together with eosinophilia &gt;1.5 x 10<sup>9</sup>/L or lower levels of blood eosinophilia with clear-cut organ involvement.</p><p>Overlap disorders include a wide variety of single organ-restricted eosinophilic disorders, such as eosinophilic gastrointestinal disorders, chronic eosinophilic pneumonia, and Well's syndrome. A number of these eosinophilic disorders can be difficult or impossible to distinguish from IHES when accompanied by blood eosinophilia &gt;1.5 x 10<sup>9</sup>/L. Whether to pursue an extensive evaluation for other end-organ involvement remains a matter of clinical judgment and should be dictated by the clinical signs and symptoms, degree of eosinophilia, and response to therapy. (See  <a class="medical medical_review" href="/d/html/4363.html" rel="external">"Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a> and  <a class="medical medical_review" href="/d/html/2536.html" rel="external">"Eosinophilic gastrointestinal diseases"</a> and  <a class="medical medical_review" href="/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia"</a> and  <a class="medical medical_review" href="/d/html/100544.html" rel="external">"Eosinophil biology and causes of eosinophilia", section on 'Disorders with eosinophilic involvement of specific organs'</a>.)</p><p class="headingAnchor" id="H295053288"><span class="h3">Specific/defined syndromes associated with HE</span><span class="headingEndMark"> — </span>Eosinophilia &gt;1.5 x 10<sup>9</sup>/L can be seen at times in a variety of conditions associated with immunodysregulation. Examples include inflammatory bowel disease, autoimmune lymphoproliferative syndrome, HIV infection, IgG4-related disease, hyperimmunoglobulin E syndromes (eg, <em>DOCK8</em> deficiency), <em>CARD9</em> deficiency, collagen vascular diseases, and sarcoidosis [<a href="#rid56">56-64</a>]. The etiology of the eosinophilia in such cases is unknown, and its impact on disease complications and clinical manifestations remains inconclusive, but it appears to correlate with the severity of the underlying condition and, in some cases, with prognosis. (See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/3960.html" rel="external">"Autosomal dominant hyperimmunoglobulin E syndrome", section on 'Dedicator of cytokinesis 8 and tyrosine kinase 2 deficiencies'</a> and  <a class="medical medical_review" href="/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a>.)</p><p class="headingAnchor" id="H4769463"><span class="h4">Episodic angioedema with eosinophilia (Gleich syndrome)</span><span class="headingEndMark"> — </span>Episodic angioedema with eosinophilia is a rare disorder characterized by recurrent episodes of angioedema, urticaria, pruritus, fever, weight gain, oliguria, elevated serum immunoglobulin M (IgM), and leukocytosis with marked blood eosinophilia. Symptoms generally appear at intervals of three to four weeks and resolve spontaneously within several days. A diuresis may occur with resolution. Based on the approximately 50 cases that have been reported, patients are typically between 10 and 34 years of age when symptoms initially develop. The contribution of eosinophils to clinical manifestations remains uncertain, although increased deposition of eosinophil granule protein in angioedematous skin has been noted. In a subset of patients with Gleich syndrome, a clonally expanded CD3-CD4+ T cell population is present. Detection of Th2 cytokines within activated CD4 T cells by flow cytometry [<a href="#rid65">65</a>] and elevated serum IL-5 levels prior to their peak hypereosinophilia [<a href="#rid65">65-67</a>] suggests that their hypereosinophilia is T cell-driven. Such patients can be classified as L-HES on a pathogenic basis. In others, the clinical presentation can be similar to L-HES, as L-HES can involve intermittent urticaria or angioedema, but T cell investigations are normal. Although development of other end-organ manifestations appears to be uncommon, this has been described [<a href="#rid68">68</a>]. Clinical flares may conserve their episodic nature over time or may progress to nonepisodic HES.</p><p>In a study of four unrelated patients, cyclic changes were found in several other cell types in addition to eosinophils, revealing that it is a multilineage disorder [<a href="#rid65">65</a>]. Neutrophils increased just before or with eosinophils, and lymphocytes rose concomitant with eosinophils. Clinical flares were also preceded by a rise in serum levels of type II cytokines (IL-5, IL-13, IL-9, and IL-10). CD3-CD4+ T lymphocytes were found in all four patients and were shown to cycle with total lymphocytes as well [<a href="#rid65">65</a>]. In another patient, periodic increases in GM-CSF, but not IL-5, were observed [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/100544.html" rel="external">"Eosinophil biology and causes of eosinophilia", section on 'Disorders with eosinophilic involvement of specific organs'</a>.)</p><p class="headingAnchor" id="H1737008861"><span class="h4">Eosinophilic granulomatosis with polyangiitis</span><span class="headingEndMark"> — </span>Eosinophilic granulomatosis with polyangiitis (EGPA, formerly called Churg-Strauss) is difficult to categorize, particularly in the absence of documented eosinophilic vasculitis on tissue biopsy. The authors prefer to view EGPA as an organ-restricted eosinophilic disorder, since it is a disease of one organ (blood vessels), although clinical manifestations can involve the sinuses, lungs, skin, heart, peripheral nerves, and other structures. However, other experts believe it is more appropriately classified as a defined syndrome associated with HE (<a class="graphic graphic_table graphicRef59869" href="/d/graphic/59869.html" rel="external">table 1</a>). This issue remains an area of debate.</p><p>In some patients presenting with HE and pulmonary disease, determining if eosinophilia and organ involvement represents chronic eosinophilic pneumonia (organ-restricted), IHES, or EGPA can be difficult clinically [<a href="#rid70">70</a>]. Many patients meet diagnostic criteria for these disorders. This is particularly challenging in the early stages of EGPA before the development of vasculitis and in patients who are antineutrophil cytoplasmic antibody (ANCA)-negative. Moreover, both disorders usually respond initially to glucocorticoids, and while glucocorticoid therapy is beneficial, it may further impede the clinician's ability to distinguish between these two conditions. Therefore, histologic assessment for vasculitis is recommended when symptoms suggest small- and medium-sized blood vessel damage, as therapeutic strategies to treat end-organ injury differ, especially for the choice of second-line agents [<a href="#rid71">71</a>]. Early in disease, pathology usually reveals eosinophil tissue infiltration without the distinguishing granulomas and frank vasculitis of late-stage EGPA [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/d/html/4347.html" rel="external">"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a> and  <a class="medical medical_review" href="/d/html/4363.html" rel="external">"Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a>.)</p><p class="headingAnchor" id="H521099149"><span class="h2">Hypereosinophilia of undetermined significance</span><span class="headingEndMark"> — </span>Patients with persistent HE of unknown etiology and no apparent organ damage or dysfunction are classified as "hypereosinophilia of undetermined significance" (HE<sub>US</sub>). Although some patients with asymptomatic HE are likely normal variants, they cannot be differentiated at the present time from patients who will ultimately progress to symptomatic HES [<a href="#rid73">73,74</a>]. (See <a class="local">'Diagnosis of hypereosinophilia of undetermined significance'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Patients may present with various combinations of symptoms and signs of end-organ damage mediated by eosinophils. In many patients, the onset of symptoms is insidious, and eosinophilia is detected incidentally. However, in others, the initial manifestations are severe and life-threatening due to the rapid evolution of cardiovascular or neurologic complications.</p><p class="headingAnchor" id="H14"><span class="h2">Signs and symptoms at presentation</span><span class="headingEndMark"> — </span>A retrospective multicenter series of 188 patients reported the frequency of specific symptoms at presentation [<a href="#rid9">9</a>]. The following types of signs and symptoms were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Dermatologic (eg, rash) – 37 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary (cough and breathlessness) – 25 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal – 14 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac – 5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic – 4 percent</p><p></p><p>Six percent of patients presented with incidentally detected and clinically asymptomatic hypereosinophilia (HE).</p><p class="headingAnchor" id="H15"><span class="h2">Cardiac disease</span><span class="headingEndMark"> — </span>Eosinophilic myocarditis is a major cause of morbidity and mortality among patients with hypereosinophilic syndrome (HES) [<a href="#rid5">5,75-77</a>]. Platelet-derived growth factor receptor alpha (<em>PDGFRA</em>)-associated HES has an increased incidence of incapacitating and potentially lethal cardiac involvement in the absence of therapy [<a href="#rid35">35</a>]. The signs and symptoms of myocarditis are described in detail separately (<a class="graphic graphic_table graphicRef66776" href="/d/graphic/66776.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults"</a>.)</p><p>Eosinophil-mediated cardiac damage involves increased numbers of eosinophils in conjunction with other ill-defined stimuli that recruit and/or activate eosinophils within the heart tissues. Extracellular deposition of eosinophil granule proteins and evidence of eosinophil activation are present at sites of myocardial injury [<a href="#rid77">77</a>]. The clinicopathologic changes in cardiac tissue associated with HES appear similar in patients with idiopathic HES (IHES) and in those with a known underlying etiology of persistent HE, including eosinophilic leukemia, granulocyte macrophage colony-stimulating factor (GM-CSF) administration, drug reactions, and parasitic infections [<a href="#rid5">5,78</a>]. (See  <a class="medical medical_review" href="/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a>.)</p><p>The development of cardiac disease in HES is unpredictable. Some patients with sustained eosinophilia never develop cardiac involvement, and the severity of cardiac injury does not clearly correlate with the degree of peripheral eosinophilia. Cardiac involvement does, however, appear to be more common in patients with the Fip1-like1-platelet-derived growth factor receptor alpha (<em>FIP1L1-PDGFRA</em>) fusion [<a href="#rid35">35,79</a>].</p><p>Eosinophil-mediated heart damage evolves through three stages, although these stages may be overlapping and not clearly sequential [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An acute necrotic stage</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An intermediate phase characterized by thrombus formation along the damaged endocardium</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A fibrotic stage characterized by altered cardiac function/heart failure due to either restrictive cardiomyopathy and/or compromise/entrapment of the chordae tendineae leading to mitral and tricuspid regurgitation</p><p></p><p>Patients with HES often develop cardiopulmonary symptoms and signs during the thrombotic and fibrotic stages.</p><p>The acute necrotic stage is characterized pathologically by endocardial damage, myocardial infiltration with eosinophils and lymphocytes, eosinophil degranulation, myocardial necrosis, and the formation of sterile microabscesses. The disease is usually clinically silent at this phase. Physical examination generally is normal, although conjunctival and/or subungual splinter hemorrhages (which probably represent small emboli from the endocardial surface) are sometimes noted. Elevations in serum troponin levels can be sensitive indicators of early and ongoing eosinophil-associated myocardial damage in forms of HES and eosinophilic granulomatosis with polyangiitis (EGPA) [<a href="#rid80">80-82</a>].</p><p>Echocardiography can be normal during the acute necrotic stage. Several reports have shown that contrast-enhanced cardiac magnetic resonance imaging (MRI) reliably detects all stages and aspects of eosinophil-mediated heart damage, including the early stage of myocardial eosinophilic inflammation (<a class="graphic graphic_diagnosticimage graphicRef82429" href="/d/graphic/82429.html" rel="external">image 1</a>) [<a href="#rid83">83,84</a>]. Endomyocardial biopsy may provide definitive evidence of eosinophil-associated cardiac involvement, but is typically reserved for patients in whom there is uncertainty whether infiltrating eosinophils are causing cardiac disease. Staining of biopsy specimens with antibodies for eosinophil granule proteins, including major basic protein 1 (MBP1), can demonstrate eosinophil-related tissue damage even in the absence of significant eosinophil accumulation [<a href="#rid85">85</a>].</p><p>The second stage of heart disease involves thrombus formation along areas of damaged endocardium. The thrombogenic sequelae of eosinophilic tissue infiltration may arise from the actions of eosinophil peroxidase in forming hypothiocyanous acid, a compound which diffuses into endothelial cells and strongly induces tissue factor expression by these cells [<a href="#rid86">86</a>]. Tissue factor, believed to be crucial in thrombus formation, is also expressed by eosinophils directly [<a href="#rid87">87</a>]. The major complication of intracardiac thrombus formation is the detachment and distant embolization of thrombotic material, leading to embolic strokes, ischemia of extremities, and other embolic events. (See <a class="local">'Thrombotic complications'</a> below and  <a class="medical medical_review" href="/d/html/5303.html" rel="external">"Echocardiography in detection of cardiac and aortic sources of systemic embolism"</a>.)</p><p>In the third fibrotic stage, fibro-inflammatory remodeling of valvular structures can lead to entrapment, rupture of chordae tendineae, or fusion of valves to the endocardial surface. Symptoms and signs present at this stage include dyspnea, chest pain, and signs of left and/or right ventricular failure. Evaluation may demonstrate mitral or tricuspid regurgitation, cardiomegaly, restrictive cardiomyopathy, or T wave inversions on the electrocardiogram. Echocardiography and cardiac MRI can show intracardiac thrombi or evidence of fibrosis, such as thickening of the posterior mitral valve leaflet or the posterior wall, late gadolinium enhancement on cardiac MRI, and increases in endomyocardial echodensity in areas of fibrosis (<a class="graphic graphic_diagnosticimage graphicRef82429" href="/d/graphic/82429.html" rel="external">image 1</a>) [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/d/html/4927.html" rel="external">"Endomyocardial fibrosis"</a> and  <a class="medical medical_review" href="/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies"</a>.)</p><p>Cardiac involvement in eosinophil-related diseases may also develop by other mechanisms, including myocardial and pericardial damage from small vessel vasculitis [<a href="#rid89">89-91</a>]. Echocardiography can evaluate myocardial function and MRI can demonstrate myocardial damage [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Neurologic disease</span><span class="headingEndMark"> — </span>HES may be complicated by cerebral thromboemboli, encephalopathy, peripheral neuropathy, or longitudinal and/or transverse sinus thrombosis [<a href="#rid93">93</a>]. Neurologic complaints, particularly those associated with cerebral thromboemboli, are occasionally the presenting symptoms of HES.</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral thromboemboli can arise from intracardiac thrombi and manifest as embolic strokes or transient ischemic episodes. MRI imaging can reveal multiple infarcts in watershed border zone distributions [<a href="#rid94">94</a>]. (See <a class="local">'Cardiac disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Encephalopathy can present with behavioral changes, confusion, ataxia, and memory loss. Affected patients may also have signs of upper motor neuron injury, such as increased muscle tone, heightened deep tendon reflexes, and a positive Babinski response. How these changes occur is not known. Encephalopathic changes are more likely with markedly elevated blood leukocyte and eosinophil numbers and may derive from microvascular occlusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral neuropathy accounts for approximately one-half of the neurologic manifestations of HES. The neuropathy may be symmetric or asymmetric, involve sensory with or without motor nerves, and may produce mononeuritis multiplex or radiculopathy with denervation muscle atrophy. (See  <a class="medical medical_review" href="/d/html/5277.html" rel="external">"Evaluation of peripheral nerve and muscle disease"</a>.)</p><p></p><p>The pathophysiology of the peripheral neuropathy in patients with HES remains largely unexplained. Biopsies of affected nerves generally show an axonal neuropathy with varying degrees of axonal loss, but no evidence of vasculitis or eosinophilic infiltration.</p><p class="headingAnchor" id="H17"><span class="h2">Thrombotic complications</span><span class="headingEndMark"> — </span>A number of case reports suggest that venous and arterial blood vessels may be damaged in HES, although the mechanisms remain largely unknown. Patients have been reported to develop femoral artery occlusion [<a href="#rid95">95</a>], intracranial sinus thrombosis [<a href="#rid96">96,97</a>], or digital gangrene in the setting of progressive Raynaud phenomenon.</p><p>Microvascular thrombosis and occlusion due to eosinophil-related damage to endothelium combined with activation of the coagulation system has been reported in association with acute renal failure and cold-induced Raynaud phenomenon causing digital necrosis [<a href="#rid5">5,98,99</a>]. While eosinophils may impact coagulation pathways at different levels, the precise mechanisms leading to hypercoagulability remain elusive [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/d/html/7553.html" rel="external">"Pathogenesis and pathophysiology of Raynaud phenomenon"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Ocular manifestations</span><span class="headingEndMark"> — </span>Ocular symptoms, particularly blurred vision, may be related to microemboli or local thrombosis [<a href="#rid5">5,100,101</a>], although uveitis has also been described.</p><p class="headingAnchor" id="H19"><span class="h2">Skin disease</span><span class="headingEndMark"> — </span>Common skin manifestations of HES include eczema (involving hands, flexural areas, or dispersed plaques), erythroderma, generalized thickening of the skin (lichenification), dermographism, recurrent urticaria, and angioedema [<a href="#rid5">5,102</a>]. Biopsies of papular or nodular lesions show perivascular infiltration with eosinophils and mild-to-moderate perivascular neutrophilic and mononuclear infiltrates without vasculitis.</p><p>Less commonly, mucosal ulcers, which are often difficult to treat, develop in the mouth, nose, pharynx, esophagus, and stomach, or on the penis or anus. Biopsy of these ulcers demonstrates a nonspecific mixed cellular infiltrate without eosinophilia, vasculitis, or microthrombi [<a href="#rid5">5</a>]. Eosinophil granule deposition may be seen on immunofluorescence staining. Several cases of HES with concomitant lymphomatoid papulosis, a T cell-mediated chronic dermatosis, have also been described [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/d/html/15725.html" rel="external">"Lymphomatoid papulosis"</a>.)</p><p>The presence and type of dermatologic lesions may provide valuable prognostic information.</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocytic variants of HES (L-HES) can present with prominent cutaneous symptoms. In the series mentioned previously, 14 of 16 L-HES patients had cutaneous lesions, including erythroderma, urticaria, and plaques [<a href="#rid14">14</a>]. Patients with cutaneous symptoms should be investigated for the presence of abnormal T cells to exclude cutaneous T cell lymphoma. Patients with L-HES should be monitored for development of T cell lymphoma. (See  <a class="medical medical_review" href="/d/html/4697.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma"</a> and  <a class="medical medical_review" href="/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who experienced angioedema and urticaria, with or without other symptoms, were likely to have a benign course without cardiac or neurologic complications, as noted in the previously mentioned series of referred HES subjects [<a href="#rid100">100,104</a>]. Some of these patients might have had the syndrome of episodic angioedema and eosinophilia (Gleich syndrome), which had not yet been recognized. (See <a class="local">'Episodic angioedema with eosinophilia (Gleich syndrome)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with mucosal ulcerations are more likely to have <em>FIP1L1-PDGFRA</em>-positive HES.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The existence of lymphomatoid papulosis should prompt a search for the <em>FIP1L1-PDGFRA</em> mutation, as this association has been reported in a small number of cases [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/d/html/15725.html" rel="external">"Lymphomatoid papulosis"</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Pulmonary disease</span><span class="headingEndMark"> — </span>Pulmonary involvement is common in HES and may result from eosinophilic infiltration of the lung with subsequent fibrosis, heart failure, or pulmonary emboli [<a href="#rid100">100</a>]. In a 2011 retrospective series of 49 patients seen at the Mayo Clinic, respiratory symptoms were reported in 63 percent of patients [<a href="#rid105">105</a>]. The most common presenting symptoms were dyspnea (45 percent), cough (39 percent), and wheezing (24 percent). Abnormal chest radiography or computed tomography (CT) findings were seen in 43 percent of patients and included parenchymal infiltrates (37 percent), pleural effusion (14 percent), intrathoracic lymphadenopathy (12 percent), and pulmonary emboli (4 percent). Infiltrates were most commonly patchy ground glass infiltrates. Of note, two of the patients with bilateral parenchymal infiltrates had no respiratory symptoms. Lung biopsy, when performed, revealed eosinophilic infiltrates. Differentiation from other diseases that cause pulmonary infiltrates with eosinophilia is reviewed separately. (See  <a class="medical medical_review" href="/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Gastrointestinal disorders</span><span class="headingEndMark"> — </span>Eosinophilic gastritis, enteritis, and/or colitis may occur secondary to HES and cause weight loss, abdominal pain, vomiting, and/or severe diarrhea [<a href="#rid5">5</a>]. Hepatic involvement may take the form of chronic active hepatitis, focal hepatic lesions, eosinophilic cholangitis, or the Budd-Chiari syndrome. (See  <a class="medical medical_review" href="/d/html/2536.html" rel="external">"Eosinophilic gastrointestinal diseases"</a> and  <a class="medical medical_review" href="/d/html/3624.html" rel="external">"Etiology of the Budd-Chiari syndrome"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">LABORATORY FEATURES</span><span class="headingEndMark"> — </span>By definition, patients must have peripheral blood hypereosinophilia (HE) (&gt;1.5 x 10<sup>9</sup>/L) (<a class="graphic graphic_picture graphicRef53980" href="/d/graphic/53980.html" rel="external">picture 1</a>) or tissue HE (as defined by the criteria discussed previously) [<a href="#rid75">75</a>]. (See <a class="local">'Definitions'</a> above.)</p><p>In peripheral blood HE, circulating eosinophils are usually mature, although eosinophilic and/or myeloid precursors may also be present. Total leukocyte counts in excess of 90 x 10<sup>9</sup>/L are associated with a poor prognosis [<a href="#rid5">5</a>].</p><p>Anemia may be present, especially in patients with the myeloproliferative variants, and either thrombocytopenia or thrombocytosis may be noted [<a href="#rid106">106</a>].</p><p>Complications of eosinophilic tissue/organ infiltration may result in elevated liver enzymes, serum troponin, and rarely, increased blood urea nitrogen and creatinine levels.</p><p>Certain abnormalities observed on routine blood tests may suggest a specific hypereosinophilic syndrome (HES) variant, including elevated serum vitamin B12 (myeloproliferative variants) or immunoglobulin E (IgE) (lymphocytic variant HES [L-HES]), although neither is entirely sensitive or specific.</p><p class="headingAnchor" id="H23"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Hypereosinophilic syndrome (HES) should be suspected in patients with persistent eosinophilia &gt;1.5 x 10<sup>9</sup>/L in the peripheral blood on at least two occasions. An evaluation should be pursued even if the patient is asymptomatic.</p><p>The initial evaluation of a patient with eosinophilia (ie, elevated but not &gt;1.5 x 10<sup>9</sup>/L) is presented separately. The specific testing required to rule out common etiologies of hypereosinophilia (HE) differs depending upon findings from a thorough history and physical examination. (See  <a class="medical medical_review" href="/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Initial studies</span><span class="headingEndMark"> — </span>The following initial tests are recommended to assess for end-organ involvement:</p><p class="bulletIndent1"><span class="glyph">●</span>Blood chemistries, including liver enzymes, creatine kinase, renal function, and troponin</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram</p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiogram</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary function tests</p><p class="bulletIndent1"><span class="glyph">●</span>Chest radiograph and computed tomography (CT)</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal CT</p><p class="bulletIndent1"><span class="glyph">●</span>Tissue biopsies and additional studies as clinically indicated</p><p></p><p>In addition, several biomarkers are under study for their predictive value regarding HES subtypes and should be measured (see <a class="local">'Diagnosis of HES subtypes'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Serum tryptase (most consistently elevated in myeloproliferative variants [M-HES], variable in other subtypes)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum vitamin B12 (elevated in M-HES)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum immunoglobulins (particularly immunoglobulin E [IgE]) (often elevated in lymphocytic variants of HES [L-HES], variable in M-HES and other subtypes)</p><p></p><p class="headingAnchor" id="H1342051994"><span class="h2">Referral</span><span class="headingEndMark"> — </span>HES is a heterogenous disorder, and patients may present to generalists or specialists. The evaluation should involve other specialists (hematology, infectious disease, allergy/immunology, pulmonary, cardiology, neurology) as dictated by the patient's specific signs and symptoms.</p><p class="headingAnchor" id="H25"><span class="h3">Hematologic evaluation</span><span class="headingEndMark"> — </span>Patients with persistent unexplained HE should undergo further evaluation to identify possible HES subtypes or underlying causes not previously identified.</p><p class="bulletIndent1"><span class="glyph">●</span>Molecular testing for the <em>FIP1L1-PDGFRA</em> mutation should be performed on peripheral blood by performing fluorescence in situ hybridization (FISH) for the <em>CHIC2</em> locus, which is located between the two fusion partners and therefore absent in the presence of the <em>FIP1L1-PDGFRA</em> fusion, or RT-PCR for the fusion transcript (commercially available in the US) [<a href="#rid31">31,107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>T lymphocyte phenotyping on peripheral blood by multiparameter flow cytometry [<a href="#rid108">108</a>], including concomitant staining and analyses for (at a minimum) CD3, CD4, and CD8 (to detect CD3-CD4+ subsets), should be performed in all cases. T cell receptor rearrangement studies on peripheral blood and/or bone marrow (available at specialty academic centers) should be done concomitantly to diagnose L-HES. (See <a class="local">'T cell lymphocytic variants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow aspiration and biopsy should be examined for cellularity, dysplasia, CD34 expression, reticulin fibrosis, mast cells, and karyotype. If these studies do not establish a diagnosis, molecular studies should be performed, including <em>FGFR1</em> and <em>PDGFRB</em> fusion genes, <em>BCR-ABL1</em>, <em>JAK2</em> V617F, <em>KIT</em> D816V, and clonal T cell receptor rearrangements.</p><p></p><p class="bulletIndent1">The bone marrow in patients with HES demonstrates increased eosinophils and eosinophil precursors. Patients with increased serum tryptase or atypical mast cells on bone marrow biopsy should also be screened for <em>KIT</em> D816V associated with systemic mastocytosis. (See <a class="local">'Myeloproliferative HES variants'</a> above and  <a class="medical medical_review" href="/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p>Cytogenetics are normal in most patients, but karyotyping plays an important role in the diagnosis of some M-HES variants. It is the only diagnostic technique for identifying cases with translocations involving <em>PDGFRB</em> and <em>FGFR1</em>. In contrast, karyotyping will not identify certain chromosomal rearrangements (eg, <em>FIP1L1-PDGFRA</em> fusion, because the interstitial deletion is small, only 800 kb) or point mutations (eg, <em>PDGFRA</em> point mutations).</p><p>Depending upon the clinical presentation and the urgency to initiate therapy, investigations may be performed sequentially, starting with those that appear more likely to be informative. For example, if a patient presents with splenomegaly, mucosal ulcers of the oral cavity, and signs of heart failure, studies aimed at evaluating etiologies of M-HES (eg, assays related to the presence of the <em>FIP1L1-PDGFRA</em> fusion) are indicated. Ideally, diagnostic testing for myeloproliferative or lymphocytic etiologies for HES should be performed expeditiously prior to initiating clinically indicated HES therapies that might suppress cell populations necessary to ascertain etiologies of HES variants.</p><p class="headingAnchor" id="H26"><span class="h2">Diagnosis of HES subtypes</span></p><p class="headingAnchor" id="H27"><span class="h3">Diagnosis of myeloproliferative variants</span><span class="headingEndMark"> — </span>Chronic eosinophilic leukemia (CEL)/M-HES are characterized by increased serum vitamin B12 levels, chromosomal abnormalities, anemia and/or thrombocytopenia, elevated serum tryptase, hepatomegaly, splenomegaly, and circulating leukocyte precursors (<a class="graphic graphic_table graphicRef59869" href="/d/graphic/59869.html" rel="external">table 1</a>). The above described hematologic evaluation may detect cytogenetic abnormalities in a subset of patients.</p><p class="bulletIndent1"><span class="glyph">●</span>In a large, retrospective, multicenter study, very high levels of vitamin B12 (&gt;2000 picograms/mL) were a marker for the presence of the <em>FIP1L1-PDGFRA</em> fusion [<a href="#rid9">9</a>]. Elevations of serum tryptase were more frequent in <em>FIP1L1-PDGFRA</em>-positive M-HES, compared with patients without the mutation (82 versus 20 percent), and mean values were higher (31 versus 19 pg/mL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another retrospective analysis of 44 patients with <em>FIP1L1-PDGFRA</em>-positive HES, the median age at diagnosis was 41 years, and all but one patient was an adult male [<a href="#rid35">35</a>]. Common laboratory findings included elevated vitamin B12 (82 percent), increased tryptase (78 percent), anemia (37 percent), thrombocytopenia (37 percent), and glucocorticoid resistance.</p><p></p><p>CEL is the result of an autonomous clonal proliferation of eosinophil precursors. Patients with CEL by definition do not demonstrate the Philadelphia chromosome or <em>BCR-ABL</em> fusion gene. As in other subtypes of HES, the peripheral blood demonstrates mature eosinophils with only a small number of eosinophilic myelocytes or promyelocytes. There may be a variety of morphologic abnormalities, including sparse granulation, cytoplasmic vacuolization, or hyper/hyposegmentation, but none of these changes are sensitive or specific for CEL. The bone marrow contains less than 20 percent blasts. The key criteria for making the diagnosis of CEL are the presence of a clonal cytogenetic or molecular genetic abnormality or blast cells that account for more than 2 or 5 percent of the peripheral blood or bone marrow, respectively [<a href="#rid21">21,109</a>].</p><p>The World Health Organization (WHO) classification system of hematopoietic and lymphoid tissues includes a special category for myeloid and lymphoid disorders with eosinophilia and abnormalities of <em>PDGFRA</em>, <em>PDGFRB</em>, <em>FGFR1</em>, or <em>PCM1-JAK2</em> [<a href="#rid110">110</a>]. Such a diagnosis is made by the identification of genetic abnormalities in any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet-derived growth factor receptor alpha (eg, the <em>FIP1L1-PDGFRA</em> fusion)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platelet-derived growth factor receptor beta (<em>PDGFRB</em>) such as t(5;12)(q31-35;p13) [<a href="#rid19">19</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibroblast growth factor receptor 1 (<em>FGFR1</em>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Janus kinase 2 (JAK2), such as a <em>PCM1-JAK2</em> fusion formed by t(8;9)(p22;p24)</p><p></p><p>Testing for <em>FIP1L1-PDGFRA</em> and <em>JAK2</em> mutations can be performed on peripheral blood and are available commercially in the United States. Tests for the less common chromosomal fusion events including <em>PDGFRB</em> and <em>FGFR1</em> are not commercially available, but karyotypes are usually abnormal in such cases.</p><p>The presence of an elevated serum tryptase concentration in the setting of myeloproliferative features may help to identify HES patients with the <em>FIP1L1-PDGFRA</em> fusion gene [<a href="#rid79">79</a>]. HES patients with elevated tryptase levels have increased numbers of mast cells on bone marrow biopsy, similar to patients with systemic mastocytosis (<a class="graphic graphic_picture graphicRef87634" href="/d/graphic/87634.html" rel="external">picture 2</a>). In both conditions, these mast cells may be morphologically abnormal (ie, spindle-shaped), although peritrabecular clustering of mast cells is uncommon in <em>PDGFRA</em>-positive disease.</p><p>It is important to distinguish <em>FIP1L1-PDGFRA</em>-positive HES patients from those with systemic mastocytosis and eosinophilia due to a mutation in c-kit, because D816V, the most common c-kit mutation, is resistant to <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, the standard therapy for <em>FIP1L1-PDGFRA</em>-positive disease [<a href="#rid13">13,111</a>]. Cases with other c-kit mutations may respond to imatinib therapy. Both c-kit mutations and <em>FIP1L1-PDGFRA</em> may coexist in a subset of patients [<a href="#rid112">112</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Rare patients with clonal eosinophilia do exist who lack myeloproliferative features. Human androgen receptor analysis (HUMARA) can be used to demonstrate clonal populations of mature eosinophils in these patients. These X-linked analyses can only be performed on females [<a href="#rid113">113,114</a>].</p><p class="headingAnchor" id="H28"><span class="h3">Diagnosis of L-HES</span><span class="headingEndMark"> — </span>T lymphocytic variants of HES (L-HES) often involve cutaneous signs and symptoms, although they can also present with cardiac, pulmonary, or neurologic events [<a href="#rid108">108</a>]. They are characterized by the following laboratory findings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal T cell surface markers</strong> – The most frequently encountered subset is CD3-CD4+, although CD3+CD4-CD8-, CD4+CD7-, and other populations of T cells have also been reported [<a href="#rid14">14,15,49,115-117</a>]. . In a subset of patients with CD3-CD4+ T cell associated disease, the proportion of aberrant cells in peripheral blood is very low (&lt;2percent), making detection by routine flow cytometry challenging. When possible, further analysis of membrane-expressed markers including CD2, CD5, and CD45RO allows a more sensitive and accurate diagnosis of this variant (higher intensity staining for CD2 and CD5 compared to normal CD4 T cells, and positivity for CD45RO). A literature review of published cases of L-HES and 2 large cohort studies confirmed that the frequency of cutaneous manifestations was especially high among patients with a CD3-CD4+ T cell [<a href="#rid45">45,46,118</a>]. Routine analyses, even multiparameter flow cytometry of CD3, CD4, and CD8 expression on lymphocytes, have not been sufficient to detect all phenotypes. In some patients with no phenotypic abnormalities on flow cytometry, clonal populations of T cells can be identified by polymerase chain reaction (PCR). However, the significance of a clonal population of T cells found by PCR alone, in the absence of abnormalities on flow cytometry, is unknown, and the diagnosis of L-HES should not be made in this situation, without some of the additional findings described below. (See <a class="local">'Skin disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T cell clonality</strong> – Clonality of phenotypically aberrant T cells has been demonstrated in many cases through analysis of T cell receptor gene rearrangement patterns. T cell receptor studies should be performed, although demonstration of T cell clonality is not sufficient to define L-HES.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytogenetic studies</strong> – Conventional chromosomal karyotypes are generally normal, although rare cases with 16q breakage, partial 6q or 10p deletions, and trisomy 7 have been reported [<a href="#rid117">117,119</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased serum IgE and polyclonal hypergammaglobulinemia</strong> – The abnormal T cells in this variant produce T helper type 2 (Th2) cytokines, leading to increased immunoglobulin E (IgE) synthesis and polyclonal hypergammaglobulinemia [<a href="#rid49">49</a>]. Serum IgE and gammaglobulin levels should be determined, although increases are neither necessary nor specific for diagnosis of L-HES [<a href="#rid108">108</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EBV infection</strong> – The development of L-HES may also be driven by chronic active Epstein-Barr virus (EBV) infection, in which eosinophilopoietic cytokines are produced by an infected T cell clone [<a href="#rid120">120</a>]. The authors routinely measure EBV DNA levels with quantitative PCR assays on blood or plasma in patients presenting with eosinophilia and a T cell clone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational tests</strong> – Elevations in serum thymus and activation-regulated chemokine (TARC) and abnormally high production of interleukin-5 (IL-5) by T cells in vitro are other abnormalities that have been reported in some patients with L-HES [<a href="#rid9">9,121,122</a>]. However, these tests are not routinely available through commercial laboratories, are costly, and can be difficult to interpret because normal values are not well-established.</p><p></p><p class="headingAnchor" id="H29"><span class="h3">Diagnosis of familial HES</span><span class="headingEndMark"> — </span>All patients should be queried about a family history of eosinophilia and/or endomyocardial fibrosis. However, routine testing of family members is of low yield and should only be performed if there is a suggestive family history or patient concern.</p><p class="headingAnchor" id="H30"><span class="h3">Diagnosis of organ-restricted HES</span><span class="headingEndMark"> — </span>Organ-restricted hypereosinophilic conditions are defined as single organ involvement together with eosinophilia &gt;1.5 x 10<sup>9</sup>/L or lower levels of blood eosinophilia with clear-cut organ involvement. (See <a class="local">'Organ-restricted hypereosinophilic conditions'</a> above.)</p><p class="headingAnchor" id="H228500522"><span class="h3">Diagnosis of specific defined syndromes associated with HE</span><span class="headingEndMark"> — </span>Overlap syndromes and associated forms of HES are described above. (See <a class="local">'Specific/defined syndromes associated with HE'</a> above.)</p><p class="headingAnchor" id="H605937813"><span class="h2">Diagnosis of hypereosinophilia of undetermined significance</span><span class="headingEndMark"> — </span>The diagnosis of hypereosinophilia of undetermined significance (HE<sub>US</sub>) is a diagnosis of exclusion and thus involves the same studies described for HES. HE is usually detected on routine complete blood count or as part of an evaluation for transient symptoms that do not prove to be related to eosinophilia, and patients must have no apparent organ damage or dysfunction. Available data regarding these patients suggests that there are no laboratory features that clearly distinguish this disorder from HES or that predict progression to HES [<a href="#rid74">74,121</a>].</p><p>In a retrospective series of 40 patients with HE<sub>US, </sub>from a single center, mean age at diagnosis was 61 (range 17 to 85) and median follow-up was 55 months (range 6 months to 19 years) [<a href="#rid74">74</a>]. Median absolute eosinophil count (AEC) was 4.2 x 10<sup>9</sup>/L (range 1.5 to 55.4 x 10<sup>9</sup>/L). One-half of patients had a leukocytosis at the time of diagnosis (mean 11.2 x 10<sup>9</sup>/L) and 65 percent had increased serum IgE levels (mean 528 int. units/mL, range 12 to 4089 int. units/mL). One patient had elevated serum B12 levels. One patient developed cardiac complications that responded to glucocorticoid therapy after 11 years of monitoring.</p><p>Another series described eight patients with HE<sub>US</sub> followed for at least five years on no therapy and compared them with patients with symptomatic HES and with normal controls [<a href="#rid121">121</a>]. Geometric mean peak AEC<sub> </sub>was 3.9 x 10<sup>9</sup>/L and 5.1 x 10<sup>9</sup>/L in patients with HE<sub>US </sub>and HES, respectively, and not<sub> </sub>statistically different. The AEC decreased over time in six patients and normalized in one after eight years. Markers of eosinophil activation were not different between patients with HE<sub>US</sub> and HES. The only statistically significant difference observed between patients with HE<sub>US </sub>and HES was the serum IgE level (98 versus 625 U/mL), indicating that increased IgE may be a predictive marker for development of eosinophil-mediated complications. However, this requires validation in a prospective study.</p><p class="headingAnchor" id="H31"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>A variety of conditions can be associated with secondary blood or tissue eosinophilia and clinical manifestations of hypereosinophilic syndromes (HES), including leukemias and lymphomas, paraneoplastic syndromes, KIT mutation-associated systemic mastocytosis with eosinophilia, drug hypersensitivity reactions, and helminth infections. These are important to diagnose, as treatment should be directed at the underlying cause rather than the eosinophilia itself. (See  <a class="medical medical_review" href="/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a>.)</p><p>The relationships among HES, acute leukemias, chronic eosinophilic leukemias (CEL), and myelodysplastic syndromes continue to be refined [<a href="#rid19">19,31,111,123,124</a>]. Patients with HES can develop T cell lymphomas or acute lymphoblastic leukemia [<a href="#rid45">45,111</a>], and patients with acute lymphocytic leukemia (ALL), especially those with pre-B cell ALL, can present clinically with HES, although molecular evidence of a clonal B lymphocyte population can usually be detected at presentation [<a href="#rid111">111,125</a>].</p><p class="headingAnchor" id="H32"><span class="h2">Acute eosinophilic leukemia</span><span class="headingEndMark"> — </span>Acute eosinophilic leukemia may be distinguished from other forms of HES by the marked increase in the number of <strong>immature</strong> eosinophils in the blood and/or marrow, the finding of greater than 10 percent blast forms in the marrow, infiltration of tissues (including the central nervous system and bones) with immature eosinophil forms, and a clinical course similar to other acute leukemias, with pronounced anemia, thrombocytopenia, and susceptibility to infection. Cardiac and neurologic complications can develop in acute eosinophilic leukemia. (See  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a>.)</p><p class="headingAnchor" id="H33"><span class="h2">Chronic myeloid or myelomonocytic leukemia</span><span class="headingEndMark"> — </span>Patients with chronic myeloid leukemia (CML) or chronic myelomonocytic leukemia (CMML) may demonstrate an absolute eosinophilia, although clinical complications due to the eosinophilia are relatively uncommon. CML can be identified by the detection of <em>BCR::ABL</em> fusion mRNA, the BCR::ABL1 protein, or the Philadelphia chromosome. CMML has a peripheral blood monocytosis and characteristic findings on bone marrow examination. Other myeloproliferative/myelodysplastic neoplasms involve a translocation between chromosomes 5 and 12, leading to autonomous tyrosine kinase activity of platelet-derived growth factor receptor beta (<em>PDGFRB</em>). (See  <a class="medical medical_review" href="/d/html/4543.html" rel="external">"Clinical manifestations and diagnosis of chronic myeloid leukemia"</a> and  <a class="medical medical_review" href="/d/html/96031.html" rel="external">"Chronic myelomonocytic leukemia: Clinical features, evaluation, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H34"><span class="h2">Systemic mastocytosis with eosinophilia</span><span class="headingEndMark"> — </span>Systemic mastocytosis with eosinophilia can be confused with Fip1-like1-platelet-derived growth factor receptor alpha (<em>FIP1L1-PDGFRA</em>)-associated disease [<a href="#rid79">79</a>]. However, systemic mastocytosis is usually associated with D816V mutations in the KIT gene. Systemic mastocytosis is characterized clinically by approximately equal sex distribution, a characteristic skin rash (urticaria pigmentosa) in more indolent forms, and prominent gastrointestinal symptoms. In contrast, HES (with the <em>FIP1L1-PDGFRA</em> mutation) demonstrates a male predominance and is associated with heart failure and restrictive pulmonary disease [<a href="#rid126">126</a>].</p><p>Aside from mutational analysis, the two disorders are most reliably distinguished by the ratio of absolute eosinophil count (AEC) to serum total tryptase (AEC/tryptase), which is &gt;100 in HES with <em>FIP1L1-PDGFRA</em> mutation, and &lt;100 in systemic mastocytosis with eosinophilia [<a href="#rid126">126</a>]. (See  <a class="medical medical_review" href="/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – The hypereosinophilic syndromes (HES) are disorders marked by the sustained overproduction of eosinophils, associated with damage to one or more organs due to eosinophilic infiltration and mediator release.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypereosinophilia (HE) in peripheral blood is defined as an absolute eosinophil count (AEC) &gt;1.5 x 10<sup>9</sup>/L (or &gt;1500 cells/microL) on two examinations (at least one month apart) and/or tissue HE defined by any of the following (see <a class="local">'Hypereosinophilia'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The percentage of eosinophils in a bone marrow section exceeds 20 percent of all nucleated cells, <strong>and/or</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A pathologist is of the opinion that tissue infiltration by eosinophils is extensive, <strong>and/or</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Marked deposition of eosinophil granule proteins is found (in the absence or presence of major tissue infiltration by eosinophils).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HES are defined as the association of HE (as defined above), with eosinophil-mediated organ damage and/or dysfunction, in which other potential causes for the damage have been excluded. (See <a class="local">'Hypereosinophilic syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– The HES are most common in patients 20 to 50 years of age, with the exception of common underlying causes of HE that can occur at any age (parasitic infection, drug allergy, neoplastic disease). The Fip1-like1-platelet-derived growth factor receptor alpha (<em>FIP1L1-PDGFRA</em>)-associated variant affects mostly males, whereas other variants appear to affect males and females in roughly equal proportions. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – HES are characterized by overproduction of eosinophils, which results either from clonal proliferation or from overproduction of eosinophilopoietic cytokines, such as interleukin 5 (IL-5). (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HES</strong> <strong>variants</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Important clinically-relevant subtypes, in which underlying molecular or immunologic defects can be identified, include myeloproliferative variants, T cell lymphocytic variants, and familial eosinophilia (<a class="graphic graphic_table graphicRef59869" href="/d/graphic/59869.html" rel="external">table 1</a>). Together, these represent 20 to 30 percent of cases. These subtypes are associated with a more clearly defined clinical presentation and prognosis, and, in the case of the <em>FIP1L1-PDGFRA</em>-associated myeloproliferative variant, response to specific therapies. (See <a class="local">'HES variants'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The majority of patients do not have an identifiable etiology and are therefore classified as "idiopathic hypereosinophilic syndrome" (IHES). In these patients, HES may be difficult to distinguish from other eosinophil-associated disorders, including eosinophilic granulomatosis with polyangiitis (EGPA). (See <a class="local">'Idiopathic HES'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypereosinophilia of undetermined significance</strong> – HE<sub>US</sub> describes patients with persistent unexplained HE, but without apparent complications related to tissue eosinophilia. This terminology highlights both the lack of an explanation for HE and the inability to predict whether the patient will eventually develop clinical manifestations related to eosinophilic organ infiltration, and thus progress to HES. (See <a class="local">'Hypereosinophilia of undetermined significance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The signs and symptoms of HES result from the overproduction of eosinophils that infiltrate and damage various tissues. The organ systems most commonly affected in HES are the skin, lungs, gastrointestinal tract, heart, and nervous system. In many patients, the onset of symptoms is insidious and eosinophilia may even be detected incidentally. In a minority, the initial manifestations are severe and life-threatening due to the rapid evolution of cardiovascular or neurologic complications. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – The diagnosis of HES should be considered in patients with sustained blood eosinophilia of &gt;1.5 x 10<sup>9</sup>/L, documented on at least two occasions, or evidence of tissue HE. Once secondary causes of eosinophilia that require therapy directed at the underlying cause are excluded (eg, helminth infection, drug hypersensitivity, and neoplastic disease), patients with persistent eosinophilia should be evaluated accordingly, regardless of the presence or absence of symptoms. This evaluation involves an assessment of end-organ involvement as well as specialized studies to identify patients with myeloproliferative or clonal lymphocytic variants. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130:607.</a></li><li><a class="nounderline abstract_t">Protheroe C, Woodruff SA, de Petris G, et al. A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2009; 7:749.</a></li><li><a class="nounderline abstract_t">Nair P, Ochkur SI, Protheroe C, et al. The identification of eosinophilic gastroenteritis in prednisone-dependent eosinophilic bronchitis and asthma. Allergy Asthma Clin Immunol 2011; 7:4.</a></li><li><a class="nounderline abstract_t">Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 2010; 126:179.</a></li><li><a class="nounderline abstract_t">Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759.</a></li><li><a class="nounderline abstract_t">Farruggia P, D'Angelo P, Acquaviva A, et al. Hypereosinophilic syndrome in childhood: clinical and molecular features of two cases. Pediatr Hematol Oncol 2009; 26:129.</a></li><li><a class="nounderline abstract_t">Rapanotti MC, Caruso R, Ammatuna E, et al. Molecular characterization of paediatric idiopathic hypereosinophilia. Br J Haematol 2010; 151:440.</a></li><li><a class="nounderline abstract_t">Williams KW, Ware J, Abiodun A, et al. Hypereosinophilia in Children and Adults: A Retrospective Comparison. J Allergy Clin Immunol Pract 2016; 4:941.</a></li><li><a class="nounderline abstract_t">Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124:1319.</a></li><li><a class="nounderline abstract_t">Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123:3574.</a></li><li class="breakAll">Spry CJF. Idiopathic hypereosinophilic syndrome. In: Eosinophils: Biological and clinical aspects, Makino S, Fukuda T (Eds), CRC, Boca Raton 1992. p.403.</li><li><a class="nounderline abstract_t">Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am 2007; 27:357.</a></li><li><a class="nounderline abstract_t">Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104:3038.</a></li><li><a class="nounderline abstract_t">Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341:1112.</a></li><li><a class="nounderline abstract_t">Vaklavas C, Tefferi A, Butterfield J, et al. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res 2007; 31:691.</a></li><li><a class="nounderline abstract_t">Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005; 19:792.</a></li><li><a class="nounderline abstract_t">Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126:45.</a></li><li><a class="nounderline abstract_t">Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003; 54:169.</a></li><li><a class="nounderline abstract_t">Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007; 27:377.</a></li><li><a class="nounderline abstract_t">Florian S, Esterbauer H, Binder T, et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res 2006; 30:1201.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</a></li><li><a class="nounderline abstract_t">Saultz JN, Kaffenberger BH, Taylor M, et al. Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome. JAMA Dermatol 2016; 152:1391.</a></li><li><a class="nounderline abstract_t">Albano F, Anelli L, Zagaria A, et al. Extramedullary molecular evidence of the 5'KIAA1509/3'PDGFRB fusion gene in chronic eosinophilic leukemia. Leuk Res 2008; 32:347.</a></li><li><a class="nounderline abstract_t">Yoshida C, Takeuchi M, Sadahira Y. A novel t(1;8)(q25;p11.2) translocation associated with 8p11 myeloproliferative syndrome. Br J Haematol 2012; 156:271.</a></li><li><a class="nounderline abstract_t">Dasari S, Naha K, Hande M, Vivek G. A novel subtype of myeloproliferative disorder? JAK2V617F-associated hypereosinophilia with hepatic venous thrombosis. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Rumi E, Milosevic JD, Casetti I, et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol 2013; 31:e269.</a></li><li><a class="nounderline abstract_t">Patterer V, Schnittger S, Kern W, et al. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Ann Hematol 2013; 92:759.</a></li><li><a class="nounderline abstract_t">Lierman E, Selleslag D, Smits S, et al. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood 2012; 120:1529.</a></li><li><a class="nounderline abstract_t">Li B, Zhang G, Li C, et al. Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL. PLoS One 2012; 7:e34912.</a></li><li><a class="nounderline abstract_t">Bacher U, Reiter A, Haferlach T, et al. A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia. Haematologica 2006; 91:817.</a></li><li><a class="nounderline abstract_t">Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201.</a></li><li><a class="nounderline abstract_t">Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003; 100:7830.</a></li><li><a class="nounderline abstract_t">Safley AM, Sebastian S, Collins TS, et al. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes Chromosomes Cancer 2004; 40:44.</a></li><li><a class="nounderline abstract_t">Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004; 104:1931.</a></li><li><a class="nounderline abstract_t">Legrand F, Renneville A, Macintyre E, et al. The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. Medicine (Baltimore) 2013.</a></li><li><a class="nounderline abstract_t">Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109:4635.</a></li><li><a class="nounderline abstract_t">Score J, Curtis C, Waghorn K, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20:827.</a></li><li><a class="nounderline abstract_t">Curtis CE, Grand FH, Musto P, et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007; 138:77.</a></li><li><a class="nounderline abstract_t">Walz C, Haferlach C, Hänel A, et al. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). Genes Chromosomes Cancer 2009; 48:179.</a></li><li><a class="nounderline abstract_t">Elling C, Erben P, Walz C, et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011; 117:2935.</a></li><li><a class="nounderline abstract_t">Khoury P, Desmond R, Pabon A, et al. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. Allergy 2016; 71:803.</a></li><li><a class="nounderline abstract_t">Helbig G, Majewski M, Wieczorkiewicz A, et al. Screening for JAK2 V617F point mutation in patients with hypereosinophilic syndrome-in response to 'Hypereosinophilic syndrome: another face of janus?' by Dahabreh et al. published in Leukemia Research, in press. Leuk Res 2009; 33:e1.</a></li><li><a class="nounderline abstract_t">Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 2010; 17:125.</a></li><li><a class="nounderline abstract_t">Wang SA, Tam W, Tsai AG, et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol 2016; 29:854.</a></li><li><a class="nounderline abstract_t">Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:389.</a></li><li><a class="nounderline abstract_t">Lefèvre G, Copin MC, Staumont-Sallé D, et al. The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. Medicine (Baltimore) 2014; 93:255.</a></li><li><a class="nounderline abstract_t">Walker S, Wang C, Walradt T, et al. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood 2016; 127:948.</a></li><li><a class="nounderline abstract_t">Ma CA, Xi L, Cauff B, et al. Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. Blood 2017; 129:650.</a></li><li><a class="nounderline abstract_t">Roufosse F, Schandené L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000; 109:540.</a></li><li><a class="nounderline abstract_t">Rioux JD, Stone VA, Daly MJ, et al. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet 1998; 63:1086.</a></li><li><a class="nounderline abstract_t">Prakash Babu S, Chen YK, Bonne-Annee S, et al. Dysregulation of interleukin 5 expression in familial eosinophilia. Allergy 2017.</a></li><li><a class="nounderline abstract_t">Collins MH, Blanchard C, Abonia JP, et al. Clinical, pathologic, and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases. Clin Gastroenterol Hepatol 2008; 6:621.</a></li><li><a class="nounderline abstract_t">Rosenfeld K, Stodell MA. Eosinophilic fasciitis in a father and son. Ann Rheum Dis 1994; 53:281.</a></li><li><a class="nounderline abstract_t">Thomson GT, MacDougall B, Watson PH, Chalmers IM. Eosinophilic fasciitis in a pair of siblings. Arthritis Rheum 1989; 32:96.</a></li><li><a class="nounderline abstract_t">Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117:1292.</a></li><li><a class="nounderline abstract_t">Ennezat PV, Noel C, Tillie-Leblond I, et al. Crohn's disease and nontropical endomyocardial fibrosis. Cardiology 2013; 125:258.</a></li><li><a class="nounderline abstract_t">Carruthers MN, Park S, Slack GW, et al. IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series. Eur J Haematol 2017; 98:378.</a></li><li><a class="nounderline abstract_t">Renston JP, Goldman ES, Hsu RM, Tomashefski JF Jr. Peripheral blood eosinophilia in association with sarcoidosis. Mayo Clin Proc 2000; 75:586.</a></li><li><a class="nounderline abstract_t">Kim YJ, Dale JK, Noel P, et al. Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome. Am J Hematol 2007; 82:615.</a></li><li><a class="nounderline abstract_t">Aspinall AI, Pinto A, Auer IA, et al. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia. Blood Cells Mol Dis 1999; 25:227.</a></li><li><a class="nounderline abstract_t">Smith KJ, Skelton HG, Drabick JJ, et al. Hypereosinophilia secondary to immunodysregulation in patients with HIV-1 disease. Arch Dermatol 1994; 130:119.</a></li><li><a class="nounderline abstract_t">Paganelli R, Scala E, Mazzone AM, et al. Th2-type cytokines, hypereosinophilia, and interleukin-5 in HIV disease. Allergy 1997; 52:110.</a></li><li><a class="nounderline abstract_t">Benfield GF, Asquith P. Blood eosinophilia and ulcerative colitis--influence of ethnic origin. Postgrad Med J 1986; 62:1101.</a></li><li><a class="nounderline abstract_t">Lanternier F, Pathan S, Vincent QB, et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med 2013; 369:1704.</a></li><li><a class="nounderline abstract_t">Khoury P, Herold J, Alpaugh A, et al. Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder. Haematologica 2015; 100:300.</a></li><li><a class="nounderline abstract_t">Gleich GJ, Schroeter AL, Marcoux JP, et al. Episodic angioedema associated with eosinophilia. N Engl J Med 1984; 310:1621.</a></li><li><a class="nounderline abstract_t">Butterfield JH, Leiferman KM, Abrams J, et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood 1992; 79:688.</a></li><li><a class="nounderline abstract_t">Wright BL, Butterfield JH, Leiferman KM, Gleich GJ. Development of eosinophilic endomyocardial disease in a patient with episodic angioedema and eosinophilia. J Allergy Clin Immunol Pract 2016; 4:336.</a></li><li><a class="nounderline abstract_t">Bochner BS, Friedman B, Krishnaswami G, et al. Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol 1991; 88:629.</a></li><li><a class="nounderline abstract_t">Khoury P, Zagallo P, Talar-Williams C, et al. Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy 2012; 67:1149.</a></li><li><a class="nounderline abstract_t">Lefèvre G, Ackermann F, Kahn JE. Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: Eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome? Autoimmun Rev 2017; 16:208.</a></li><li><a class="nounderline abstract_t">Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol 2001; 14:1284.</a></li><li><a class="nounderline abstract_t">Chen YY, Khoury P, Ware JM, et al. Marked and persistent eosinophilia in the absence of clinical manifestations. J Allergy Clin Immunol 2014; 133:1195.</a></li><li><a class="nounderline abstract_t">Helbig G, Hus M, Francuz T, et al. Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance. Med Oncol 2014; 31:815.</a></li><li><a class="nounderline abstract_t">Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54:1.</a></li><li><a class="nounderline abstract_t">Take M, Sekiguchi M, Hiroe M, et al. Clinical spectrum and endomyocardial biopsy findings in eosinophilic heart disease. Heart Vessels Suppl 1985; 1:243.</a></li><li><a class="nounderline abstract_t">Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:457.</a></li><li><a class="nounderline abstract_t">Chew CY, Ziady GM, Raphael MJ, et al. Primary restrictive cardiomyopathy. Non-tropical endomyocardial fibrosis and hypereosinophilic heart disease. Br Heart J 1977; 39:399.</a></li><li><a class="nounderline abstract_t">Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660.</a></li><li><a class="nounderline abstract_t">Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003; 102:3456.</a></li><li><a class="nounderline abstract_t">Gertz MA. Troponin in hematologic oncology. Leuk Lymphoma 2008; 49:194.</a></li><li><a class="nounderline abstract_t">Zaky J, Caraang C, Yu R, El-Bialy A. Elevated troponins and the Churg-Strauss syndrome: a case report. J Cardiovasc Pharmacol Ther 2005; 10:131.</a></li><li><a class="nounderline abstract_t">Debl K, Djavidani B, Buchner S, et al. Time course of eosinophilic myocarditis visualized by CMR. J Cardiovasc Magn Reson 2008; 10:21.</a></li><li><a class="nounderline abstract_t">Syed IS, Martinez MW, Feng DL, Glockner JF. Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. Int J Cardiol 2008; 126:e50.</a></li><li><a class="nounderline abstract_t">Wright BL, Leiferman KM, Gleich GJ. Eosinophil granule protein localization in eosinophilic endomyocardial disease. N Engl J Med 2011; 365:187.</a></li><li><a class="nounderline abstract_t">Wang JG, Mahmud SA, Thompson JA, et al. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 2006; 107:558.</a></li><li><a class="nounderline abstract_t">Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 2007; 109:995.</a></li><li><a class="nounderline abstract_t">Plastiras SC, Economopoulos N, Kelekis NL, Tzelepis GE. Magnetic resonance imaging of the heart in a patient with hypereosinophilic syndrome. Am J Med 2006; 119:130.</a></li><li><a class="nounderline abstract_t">Cereda AF, Pedrotti P, De Capitani L, et al. Comprehensive evaluation of cardiac involvement in eosinophilic granulomatosis with polyangiitis (EGPA) with cardiac magnetic resonance. Eur J Intern Med 2017; 39:51.</a></li><li><a class="nounderline abstract_t">Zhu D, Luo Y, Liu X, Zu L. Antiproteinase 3 Positive Eosinophilic Granulomatosis with Polyangiitis Presenting with Heart Failure and Intraventricular Thrombosis. Case Rep Rheumatol 2017; 2017:2908185.</a></li><li><a class="nounderline abstract_t">Saito Y, Okada S, Funabashi N, Kobayashi Y. ANCA-negative eosinophilic granulomatosis with polyangitis (EGPA) manifesting as a large intracardiac thrombus and glomerulonephritis with angionecrosis. BMJ Case Rep 2016; 2016.</a></li><li><a class="nounderline abstract_t">Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65:270.</a></li><li><a class="nounderline abstract_t">Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 1985; 102:109.</a></li><li><a class="nounderline abstract_t">Aida L, Parkhutik V, Tembl JI, et al. Embolism and impaired washout: a possible explanation of border zone strokes in hypereosinophilic syndrome. J Neurol Sci 2013; 325:162.</a></li><li><a class="nounderline abstract_t">Kawata E, Kuroda J, Wada K, et al. Hypereosinophilic syndrome accompanied by Buerger's disease-like femoral arterial occlusions. Intern Med 2007; 46:1919.</a></li><li><a class="nounderline abstract_t">Sakuta R, Tomita Y, Ohashi M, et al. Idiopathic hypereosinophilic syndrome complicated by central sinovenous thrombosis. Brain Dev 2007; 29:182.</a></li><li><a class="nounderline abstract_t">Numagami Y, Tomita T, Murakami K, et al. Sinus thrombosis in idiopathic hypereosinophilic syndrome causing fatal cerebral haemorrhage. J Clin Neurosci 2008; 15:585.</a></li><li><a class="nounderline abstract_t">Spry CJ, Davies J, Tai PC, et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983; 52:1.</a></li><li><a class="nounderline abstract_t">Liapis H, Ho AK, Brown D, et al. Thrombotic microangiopathy associated with the hypereosinophilic syndrome. Kidney Int 2005; 67:1806.</a></li><li><a class="nounderline abstract_t">Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97:78.</a></li><li><a class="nounderline abstract_t">Chaine G, Davies J, Kohner EM, et al. Ophthalmologic abnormalities in the hypereosinophilic syndrome. Ophthalmology 1982; 89:1348.</a></li><li><a class="nounderline abstract_t">Leiferman KM, Gleich GJ, Peters MS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:415.</a></li><li><a class="nounderline abstract_t">McPherson T, Cowen EW, McBurney E, Klion AD. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis. Br J Dermatol 2006; 155:824.</a></li><li><a class="nounderline abstract_t">Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 1981; 58:1021.</a></li><li><a class="nounderline abstract_t">Dulohery MM, Patel RR, Schneider F, Ryu JH. Lung involvement in hypereosinophilic syndromes. Respir Med 2011; 105:114.</a></li><li><a class="nounderline abstract_t">Flaum MA, Schooley RT, Fauci AS, Gralnick HR. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood 1981; 58:1012.</a></li><li><a class="nounderline abstract_t">Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102:3093.</a></li><li><a class="nounderline abstract_t">Carpentier C, Schandené L, Dewispelaere L, et al. CD3-CD4+ Lymphocytic Variant Hypereosinophilic Syndrome: Diagnostic Tools Revisited. J Allergy Clin Immunol Pract 2021; 9:2426.</a></li><li class="breakAll">World Health Organization classification of tumours of haematopoietic and lymphoid tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a class="nounderline abstract_t">Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 2022; 97:129.</a></li><li><a class="nounderline abstract_t">Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol 2004; 77:82.</a></li><li><a class="nounderline abstract_t">Schmitt-Graeff AH, Erben P, Schwaab J, et al. The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia. Blood 2014; 123:595.</a></li><li><a class="nounderline abstract_t">Luppi M, Marasca R, Morselli M, et al. Clonal nature of hypereosinophilic syndrome. Blood 1994; 84:349.</a></li><li><a class="nounderline abstract_t">Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 1999; 93:1651.</a></li><li><a class="nounderline abstract_t">Cogan E, Schandené L, Crusiaux A, et al. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994; 330:535.</a></li><li><a class="nounderline abstract_t">Simon HU, Yousefi S, Dommann-Scherrer CC, et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996; 183:1071.</a></li><li><a class="nounderline abstract_t">Kitano K, Ichikawa N, Mahbub B, et al. Eosinophilia associated with proliferation of CD(3+)4-(8-) alpha beta+ T cells with chromosome 16 anomalies. Br J Haematol 1996; 92:315.</a></li><li><a class="nounderline abstract_t">Carpentier C, Verbanck S, Schandené L, et al. Eosinophilia Associated With CD3-CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients. Front Immunol 2020; 11:1765.</a></li><li><a class="nounderline abstract_t">Ravoet M, Sibille C, Roufosse F, et al. 6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica 2005; 90:753.</a></li><li><a class="nounderline abstract_t">Klion AD, Mejia R, Cowen EW, et al. Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome. Blood 2013; 121:2364.</a></li><li><a class="nounderline abstract_t">Chen R, Giliani S, Lanzi G, et al. Whole-exome sequencing identifies tetratricopeptide repeat domain 7A (TTC7A) mutations for combined immunodeficiency with intestinal atresias. J Allergy Clin Immunol 2013; 132:656.</a></li><li><a class="nounderline abstract_t">de Lavareille A, Roufosse F, Schmid-Grendelmeier P, et al. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 2002; 110:476.</a></li><li><a class="nounderline abstract_t">Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003; 121:203.</a></li><li><a class="nounderline abstract_t">Bain BJ. Hypereosinophilia. Curr Opin Hematol 2000; 7:21.</a></li><li><a class="nounderline abstract_t">Fridman A, Sagiv Sh, Shvidel L, Berrebi A. Reversible Horner syndrome caused by solitary plasmacytoma of second thoracic vertebrae. Leuk Lymphoma 2004; 45:2531.</a></li><li><a class="nounderline abstract_t">Maric I, Robyn J, Metcalfe DD, et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007; 120:680.</a></li></ol></div><div id="topicVersionRevision">Topic 2211 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22460074" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19345285" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21362188" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The identification of eosinophilic gastroenteritis in prednisone-dependent eosinophilic bronchitis and asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20639012" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8180373" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19382034" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hypereosinophilic syndrome in childhood: clinical and molecular features of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20955401" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Molecular characterization of paediatric idiopathic hypereosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27130711" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hypereosinophilia in Children and Adults: A Retrospective Comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910029" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687085" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687085" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868854" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284118" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10511609" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17095087" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15772698" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20639008" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Refining the definition of hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525672" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The hypereosinophilic syndrome revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868855" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16406018" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27681117" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17681599" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Extramedullary molecular evidence of the 5'KIAA1509/3'PDGFRB fusion gene in chronic eosinophilic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21848523" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A novel t(1;8)(q25;p11.2) translocation associated with 8p11 myeloproliferative syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23997080" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A novel subtype of myeloproliferative disorder? JAK2V617F-associated hypereosinophilia with hepatic venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23630205" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23400675" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22899477" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22523564" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769584" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660384" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12808148" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034867" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15166033" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23982058" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299092" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16498388" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17555450" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19006078" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21224473" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797802" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18466967" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Screening for JAK2 V617F point mutation in patients with hypereosinophilic syndrome-in response to 'Hypereosinophilic syndrome: another face of janus?' by Dahabreh et al. published in Leukemia Research, in press.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20075725" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27174585" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868856" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lymphocytic variant hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25398061" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26702067" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27956386" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886202" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9758611" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28226398" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Dysregulation of interleukin 5 expression in familial eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18434257" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical, pathologic, and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8203961" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Eosinophilic fasciitis in a father and son.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2912468" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Eosinophilic fasciitis in a pair of siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16750989" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23839293" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Crohn's disease and nontropical endomyocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28005278" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852419" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Peripheral blood eosinophilia in association with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17266055" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10575548" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8285733" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Hypereosinophilia secondary to immunodysregulation in patients with HIV-1 disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062639" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Th2-type cytokines, hypereosinophilia, and interleukin-5 in HIV disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3658847" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Blood eosinophilia and ulcerative colitis--influence of ethnic origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24131138" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Deep dermatophytosis and inherited CARD9 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25527564" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6727934" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Episodic angioedema associated with eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732010" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26563671" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Development of eosinophilic endomyocardial disease in a patient with episodic angioedema and eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1918729" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22775568" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27915050" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: Eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11743052" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Recent advances in the diagnosis of Churg-Strauss syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23987798" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Marked and persistent eosinophilia in the absence of clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24338273" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1090795" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3843586" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Clinical spectrum and endomyocardial biopsy findings in eosinophilic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868859" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cardiovascular manifestations of hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/869976" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Primary restrictive cardiomyopathy. Non-tropical endomyocardial fibrosis and hypereosinophilic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12676775" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14568908" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18231905" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Troponin in hematologic oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965564" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Elevated troponins and the Churg-Strauss syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18466607" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Time course of eosinophilic myocarditis visualized by CMR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17399811" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21751935" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Eosinophil granule protein localization in eosinophilic endomyocardial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16166591" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17003379" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Eosinophils are a major intravascular location for tissue factor storage and exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443414" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Magnetic resonance imaging of the heart in a patient with hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27727077" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Comprehensive evaluation of cardiac involvement in eosinophilic granulomatosis with polyangiitis (EGPA) with cardiac magnetic resonance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28251013" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Antiproteinase 3 Positive Eosinophilic Granulomatosis with Polyangiitis Presenting with Heart Failure and Intraventricular Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27591039" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : ANCA-negative eosinophilic granulomatosis with polyangitis (EGPA) manifesting as a large intracardiac thrombus and glomerulonephritis with angionecrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23044708" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2981493" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Neurologic dysfunction in the idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23290568" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Embolism and impaired washout: a possible explanation of border zone strokes in hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057765" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hypereosinophilic syndrome accompanied by Buerger's disease-like femoral arterial occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16996710" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Idiopathic hypereosinophilic syndrome complicated by central sinovenous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18308571" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Sinus thrombosis in idiopathic hypereosinophilic syndrome causing fatal cerebral haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6878618" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Clinical features of fifteen patients with the hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840027" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Thrombotic microangiopathy associated with the hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7046556" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7162780" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Ophthalmologic abnormalities in the hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868857" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Dermatologic manifestations of the hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16965435" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7197566" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21036585" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Lung involvement in hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7197565" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12842979" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33545400" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : CD3-CD4+ Lymphocytic Variant Hypereosinophilic Syndrome: Diagnostic Tools Revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33545400" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : CD3-CD4+ Lymphocytic Variant Hypereosinophilic Syndrome: Diagnostic Tools Revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34533850" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307112" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24458279" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8018930" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Clonal nature of hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10029594" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Clonality of isolated eosinophils in the hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8302319" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8642249" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8602991" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Eosinophilia associated with proliferation of CD(3+)4-(8-) alpha beta+ T cells with chromosome 16 anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32849632" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Eosinophilia Associated With CD3-CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15951288" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : 6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23520331" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23830146" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Whole-exome sequencing identifies tetratricopeptide repeat domain 7A (TTC7A) mutations for combined immunodeficiency with intestinal atresias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209097" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694242" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : The eosinophilias, including the idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10608500" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Hypereosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15621774" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Reversible Horner syndrome caused by solitary plasmacytoma of second thoracic vertebrae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17628645" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
